Clinical Trial Update: Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial compared amrubicin to topotecan in patients with small cell lung cancer who had responded to prior therapy. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Amrubicin (amrubicin)
• Topotecan (topotecan)

Snippet

Sponsor: Celgene Corporation | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED